Status:
COMPLETED
A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®
Lead Sponsor:
Amgen
Conditions:
Anemia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this trial is to prospectively assess the relationship between changes in hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients receiving chemotherapy...
Eligibility Criteria
Inclusion
- Subjects with nonmyeloid malignancy(ies)
- Anemia (hgb less than or equal to 11.0 g/dL) due to cancer and chemotherapy
Exclusion
- Subjects with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndromes (MDS)
- Unstable cardiac disease or anemia due to other causes
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
End Date :
December 1 2003
Estimated Enrollment :
2423 Patients enrolled
Trial Details
Trial ID
NCT00117117
Start Date
September 1 2002
End Date
December 1 2003
Last Update
March 25 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.